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Abstract: For many years the neuromodulator adenosine has been recognized as an endogenous anticonvulsant molecule 
and termed a “retaliatory metabolite.” As the core molecule of ATP, adenosine forms a unique link between cell energy 
and neuronal excitability. In parallel, a ketogenic (high-fat, low-carbohydrate) diet is a metabolic therapy that influences 
neuronal activity significantly, and ketogenic diets have been used successfully to treat medically-refractory epilepsy, par-
ticularly in children, for decades. To date the key neural mechanisms underlying the success of dietary therapy are un-
clear, hindering development of analogous pharmacological solutions. Similarly, adenosine receptor–based therapies for 
epilepsy and myriad other disorders remain elusive. In this review we explore the physiological regulation of adenosine as 
an anticonvulsant strategy and suggest a critical role for adenosine in the success of ketogenic diet therapy for epilepsy. 
While the current focus is on the regulation of adenosine, ketogenic metabolism and epilepsy, the therapeutic implications 
extend to acute and chronic neurological disorders as diverse as brain injury, inflammatory and neuropathic pain, autism 
and hyperdopaminergic disorders. Emerging evidence for broad clinical relevance of the metabolic regulation of adeno-
sine will be discussed. 
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INTRODUCTION 
  Adenosine  is  a  potent  neuromodulatory  purine  present 
throughout the extracellular space of the central nervous sys-
tem.  Adenosine  acts  at  pre-  and  postsynaptic  G  protein-
coupled receptor subtypes (A1, A2A, A2B, and A3) [58], and 
the influence of A1 and A2A receptor subtypes predominates 
due to their higher affinity for adenosine (~100 nM) [100] 
and their activation by ongoing levels of adenosine. In brain, 
A1 receptors are distributed widely [73] and A2A receptors 
are located preferentially in the basal ganglia and olfactory 
tubercle  [169].  Both  the  A1  and  A2  receptor  subtypes  are 
antagonized by caffeine, the most widely used psychoactive 
substance worldwide, and caffeine’s actions at adenosine A1 
and A2A receptors in the central nervous system underlie its 
alerting, locomotor and cognitive effects [136].  
  Adenosine exerts a tonic inhibition of neuronal excitabil-
ity via A1 receptors in many brain regions, including hippo-
campus and cerebral cortex, and this baseline inhibition in-
fluences both baseline synaptic activity [132, 175] and neu-
ronal  plasticity  [36].  Adenosine’s  inhibitory  influence  also 
alters seizure threshold directly, and increased extracellular 
adenosine during a seizure plays a key role in postictal de-
pression [193] and in keeping a seizure focus localized [140] 
via adenosine A1 receptors [74]. Large additional amounts of 
adenosine are mobilized during metabolically stressful cellu-
lar conditions such as low oxygen or glucose [57], and in-
creased  extracellular  adenosine  acting  at  the  adenosine A 1 
receptor has been shown to be neuroprotective during condi-
tions of metabolic stress [45]. Overall, adenosine holds well 
established and profound therapeutic potential for conditions 
such as stroke, brain injury, pain and epilepsy, among others 
[17, 79]. 
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  Whereas adenosine’s role as an endogenous neuroprotec-
tive molecule during pathology such as stroke, hypoxia and 
brain  injury  is  of  paramount  clinical  importance,  and  has 
long been the focus on adenosine-based therapies, the ongo-
ing effects of adenosine are critical to baseline neuronal ex-
citability and sleep behaviors. In addition, adenosine influ-
ences the risk for an epileptic seizure, and can control sig-
nificantly the expression and progression of a broad range of 
acute and chronic neurological conditions. With an unparal-
leled long-term epidemiological database based on manipu-
lating the influence of endogenous adenosine, i.e. the world-
wide consumption of caffeine [60, 85], a strategy focused on 
regulating endogenous adenosine is likely to be well toler-
ated and non-toxic.  
  To date, receptor-based strategies to augment the inhibi-
tory influence of adenosine by targeting A 1 receptors have 
been unable to harness its clinical potential, primarily due to 
peripheral  side  effects  [43,  51].  Accordingly,  interest  has 
intensified in the regulation of adenosine directly by physio-
logical stimulation [42, 45, 76, 77], metabolism [125] and 
adenosine  kinase  [75],  an  astrocytic  intracellular  enzyme 
that, together with equilibrative adenosine transport, controls 
extracellular adenosine levels. We now appreciate the active 
role of astrocytes in regulating extracellular adenosine [156], 
underscoring  the  multi-faceted  and  direct  impact  that  glia 
have on neuronal activity and signaling. Together, these re-
cent findings highlight the dynamic regulation of adenosine 
by cellular and metabolic stimuli, and thus expose new clini-
cally-relevant strategies for augmenting adenosine.  
ADENOSINE:  A  KEY  LINK  BETWEEN  METABO-
LISM AND NEURONAL SIGNALING 
  As both the core of ATP and a prevalent neuromodulator, 
adenosine is poised to link changes in cell metabolism with 
changes in neuronal activity [109]. Indeed, adenosine levels 
rise dramatically in the extracellular space during all types of 258    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
metabolic  stress  and earned adenosine  the  apt  title of  “re-
taliatory metabolite” [138] - its profound inhibitory influence 
at both pre- and postsynaptic receptors serves to limit energy 
demand and excitotoxicity when energy availability is com-
promised [59]. The direct release of adenosine via nucleoside 
transporters  can  increase  extracellular  adenosine  under 
physiologically  stressful  conditions  [114],  and  typically 
adenosine’s role as a retaliatory metabolite is thought to be 
mobilized  when  intracellular  ATP  dephosphorylation  out-
strips ATP production [145, 170]. However, the regulation of 
adenosine by ongoing physiological stimuli and under non-
pathological conditions of adequate or even high intracellular 
ATP is becoming more appreciated [45, 96, 128]. In addi-
tion, degradation of extracellular ATP is a major source of 
extracellular  adenosine  [29,  44,  82],  so  manipulations  that 
increase extracellular ATP have a net effect on neuromodu-
lation by adenosine [44]. 
  Ketogenic strategies such as fasting or adhering to a ke-
togenic (high-fat, low-carbohydrate) diet increase ATP and 
other energy molecules in brain [20, 37, 126, 134]. These 
metabolic manipulations are known to reduce seizures sig-
nificantly [194], and have been shown to offer neuroprotec-
tion in animal models of brain injury [70, 125]. Emerging 
evidence  suggests  that  mimicking  key  cellular  aspects  of 
ketogenic metabolism increases extracellular adenosine [96], 
and furthermore, that an increased influence of adenosine at 
the A1 subtype plays a key role in the anticonvulsant success 
of  ketogenic  strategies  [127]  via  its  combined  presynaptic 
inhibition  of  glutamatergic  terminals  and  its  postsynaptic 
hyperpolarization  via K
+  channels.  Due  to  the  functional 
coupling  and  inverse  relationship  between  adenosine  and 
dopamine receptors (A2A/D2 and A1/D1) [66], a general in-
crease in extracellular adenosine could also decrease dopa-
minergic  transmission.  A  diverse  set  of  physiological  and 
pathological  stimuli  that  modulate  extracellular  adenosine 
are outlined in Table 1.  
Table 1.  Conditions that Increase Adenosine in the CNS 
Manipulation  Reference 
Hypoxia 
Fowler 1989 [55] 
Dale & Frenguelli 2000 [34] 
Saransaari & Oja 2003 [172] 
Martín, Fernández, Perea, Pascual, Haydon, 
Araque & Ceña 2007 [123] 
Ischemia 
Fowler 1990 [56] 
Latini, Corsi, Pedata & Pepeu 1995 [108] 
Frenguelli, Llaudet & Dale 2003 [63] 
Parkinson, Xiong & Zamzow 2005 [155] 
Frenguelli, Wigmore, Llaudet & Dale 2007 [64] 
NMDA receptor 
activation 
Manzoni, Manabe & Nicoll 1994 [119] 
Semba & White 1997 [176] 
Melani, Corsi, Giménez-Llort, Martínez, Ogren, 
Pedata & Ferré 1999 [130] 
Brambilla, Chapman & Greene 2005 [21] 
(Table 1. Contd….) 
Manipulation  Reference 
H2O2 
Masino, Mesches, Bickford & Dunwiddie  
1999 [129] 
Saransaari & Oja 2003 [172] 
Hypoglycemia or  
 impaired glycolysis 
Fowler 1993 [57] 
Zhu & Krnjević 1993 [201] 
Calabresi, Centonze, Pisani & Bernardi 1997 
[22] 
Zhao, Tekkök & Krnjević [200] 
Minor, Rowe, Soames Job, Ferguson [131] 
Increased tempera-
ture 
Gabriel, Klussman & Igelmund 1998 [67] 
Masino & Dunwiddie 1999 [124] 
Hypercap-
nia/acidification 
Dulla, Dobelis, Pearson, Frenguelli, Staley & 
Masino 2005 [42] 
Gourine, Llaudet, Dale & Spyer 2005 [77] 
Otsuguro, Yamaji, Ban, Ohta & Ito 2006 [146] 
Depolarization 
Pedata, Pazzagli, Tilli & Pepeu 1990 [157] 
Latini, Corsi, Pedata & Pepeu 1995 [108] 
Metabolic poisons 
Doolette1997 [40] 
Zhu & Krnjević 1997 [202] 
Saransaari & Oja 2003 [172] 
Astrocyte activation 
Zhang, Wang, Ye, Ge, Chen, Jiang, Wu, Poo & 
Duan 2003 [199] 
Parkinson & Xiong 2004 [154] 
Pascual, Casper, Kubera, Zhang, Revilla-
Sanchez, Sul, Takano, Moss, McCarthy & Hay-
don  
2005 [156] 
Seizures 
Whitcomb, Lupica, Rosen & Berman 1990 [193] 
During & Spencer 1993 [46] 
Berman, Fredholm, Aden & O’Connor 2000 
[11] 
Kaku, Jiang, Hada, Morimoto & Hayashi 2001 
[93] 
Etherington, Patterson, Meechan, Boison, 
Irving, Dale & Frenguelli 2008 [52] 
Intense exercise  Dworak, Diel, Voss, Hollman & Strüder 2007 
[47] 
Sleep deprivation 
Porkka-Heiskanen, Strecker, Thakkar, Bjorkum, 
Greene & McCarley 1997 [162]  
Porkka-Heiskanen, Strecker & McCarley  
2000 [161] 
Kalinchuk, McCarley, Stenberg, Porkka-
Heiskanen & Basheer 2008 [94] 
Murillo-Rodriguez, Liu, Blanco-Centurion & 
Shiromani, 2008 [133] 
An overview of both physiological and pathological conditions of altered metabolism 
and  cellular  activity  that  can  increase  extracellular  adenosine.  Due  to  the  rapid 
dephosphorylation  of  extracellular  ATP  to  adenosine,  increased  extracellular  ATP 
yields a net increase in adenosine. This table is not meant to be exhaustive of the litera-
ture, but to highlight the ubiquitous and rapid nature of the adenosine response and thus 
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ADENOSINE, METABOLISM AND EPILEPSY 
  The  inhibitory  adenosine  A1  receptor  is  functionally 
dominant in hippocampus and cerebral cortex, and underlies 
adenosine’s role as an endogenous anticonvulsant [43]. Ac-
cordingly,  any  manipulation  which  increases  extracellular 
adenosine offers significant potential for both preventing and 
halting epileptic seizures, the vast majority of which initiate 
and propagate in these forebrain regions. Unlike the point-to-
point and activity-dependent changes in synaptic  transmis-
sion effected by classical neurotransmitters, adenosine exerts 
a tonic modulatory influence on neuronal activity. Thus the 
anticonvulsant effects of adenosine are dissimilar mechanis-
tically to classical actions of glutamate and GABA, the neu-
rotransmitters targeted most often for the treatment of epi-
lepsy [168]. Adenosine itself is not packaged in vesicles, and 
its non-synaptic release, such as from astrocytes and through 
nucleoside  transporters,  can  influence  a  neural  “neighbor-
hood.” Akin to a broad-based influence of altered metabo-
lism, such as via ketogenic strategies, the presence of a tonic 
level of adenosine in the extracellular space makes adenosine 
a major player in the dynamics of nervous system activity 
and even in determining the set point of normal physiology 
versus pathology in brain function – such as by determining 
seizure  threshold.  Indeed,  local  release  of  adenosine  itself 
[89] or regulating local metabolism of adenosine by reducing 
its intracellular rephosphorylation by adenosine kinase [18] 
both  offer  significant  emerging  potential  for  treating  epi-
lepsy.  Importantly,  adenosine  is  effective  in  stopping  sei-
zures which  are pharmacoresistant [16], thus opening new 
therapeutic opportunities for intractable epilepsy. 
  Physiological conditions which offer both high ATP lev-
els  and  increased  extracellular  adenosine  are  particularly 
ideal for epilepsy and for many acute and chronic neurologi-
cal  disorders  characterized  by  metabolic  dysfunction  and 
neuronal vulnerability or frank progressive neurodegenera-
tion.  Enhanced  ATP  levels  provide  energy  reserves  for  a 
neuron  to  continue  functioning  under  stress,  essential  for 
maintaining cell calcium and other ion gradients across the 
cell  and  mitochondrial  membrane.  Increased  extracellular 
adenosine, at levels permitting normal synaptic transmission, 
plasticity  and  cognition,  offers  a  neuroprotective  buffer 
against insults, reduces excitation, and averts excessive ATP 
demand, expressly critical in cells with compromised energy 
capacity. Ideally, metabolic strategies enhance ATP, increase 
extracellular  adenosine,  and  boost  on-demand  adenosine 
within a neural neighborhood to provide local seizure control 
and neuroprotection. As such, metabolic and dietary strate-
gies such as ketogenic diet therapy may increase regional or 
global  adenosine  and  increase  overall  seizure  threshold  as 
described below. 
THE  REGULATION  OF  ADENOSINE  AND  BIO-
ENERGETICS BY KETOGENIC METABOLISM 
  Multiple lines of evidence suggest that adenosine, ATP, 
and  general  cellular  energy  are  upregulated  by  ketogenic 
metabolism. To highlight these effects, it is necessary to re-
view  the  underlying  biochemistry  of  ketosis.  Due  to  re-
stricted carbohydrate intake, blood glucose is very low dur-
ing chronic consumption of a ketogenic diet (or prolonged 
fasting). During conditions of limited glucose the liver main-
tains energy homeostasis by converting fatty acids and some 
amino acids to ketone bodies (β-hydroxybutyrate, acetoace-
tate,  acetone)  which  are  then  transported  by  the  blood  to 
other tissues for use as fuel. The brain is particularly depend-
ent on this process, since it is poor both at using fatty acids 
directly for fuel and at converting fatty acids to ketone bod-
ies;  the  brain  is  a  unique  tissue  in  this  regard  [65,  147]. 
While  the  enzymes  involved  in  ketone  body  synthesis  are 
detectable in brain, they are present at far lower levels than 
in liver [4, 27, 28].  
  Ketone bodies lead to energy production by conversion 
to  acetyl-CoA  which  then  enters  the  mitochondrial  tricar-
boxylic acid cycle, replacing pyruvate (derived from glyco-
lysis) as an acetyl-CoA source. The tricarboxylic acid cycle 
then leads as usual to proton flow out of the mitochondria 
matrix; this gradient in turn powers ATP production by ATP 
synthase in the mitochondrial inner membrane. Not only can 
ketone bodies substitute for glucose, metabolism of ketone 
bodies is more efficient than that of glucose, leading to more 
available energy for ATP synthesis. This effect derives from 
the higher heat of combustion of ketone bodies compared to 
pyruvate [187]; ketone body metabolism leads to reduction 
of the mitochondrial NAD couple (NAD
+/NADH) and oxi-
dation of the mitochondrial co-enzyme Q couple (Q/QH2). 
The difference between the redox potentials of these couples 
determines  the  magnitude  of  the  proton  gradient  which  in 
turn determines the free energy (ΔG’) of ATP hydrolysis – 
the increased difference with ketone body metabolism leads 
to increased ΔG’ for ATP production [187]. Key aspects of 
this energy cycle and its relationship to adenosine are sum-
marized in Fig. (1). 
  Experimental application of ketone bodies in vitro leads 
to increased ATP/ADP  and phosphocreatine/creatine ratios 
and increased levels of the tricarboxylic acid cycle substrates 
citrate and isocitrate [95, 173]. Overall, studies of ketogenic 
metabolism in the brain demonstrate an increased energetic 
status using measures ranging from respiration to mitochon-
drial density to levels of energy-storing substances such as 
ATP and phosphocreatine. Importantly, the brain’s bioener-
getic response to ketosis  appears  to differ from peripheral 
tissues so far examined – increases in cell energy predomi-
nate in brain (Table 2). 
  In addition to published neurochemical and biochemical 
evidence, recent neurochemical evidence suggests a regional 
upregulation of energy molecules in rats after maintenance 
on  a  ketogenic  diet.  Preliminary  results  demonstrate  in-
creased  ATP  or  adenosine  in  specific  brain  regions  [127, 
143], including a significant increase in ATP and a strong 
trend toward increased  adenosine  in cerebral  cortex [127], 
and  upregulated  ATP  synthase  gene  expression  in  hippo-
campus [20, 141]. Field recordings from the CA1 region of 
hippocampal slices show a reduced electrophysiological re-
sponse to hypoxia [20] and exogenous adenosine [127] after 
ketogenic diet therapy, consistent with increased endogenous 
adenosine. Hippocampal CA3 pyramidal neurons autoregu-
late  their  activity  based  on  acute  changes  in  intracellular 
ATP and extracellular glucose consistent with the metabolic 
consequences of ketogenic diet therapy [96]; detailed cellular 
mechanisms are described below.  260    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
  As  noted  above,  ketogenic  metabolism  occurs  during 
restricted  glucose  and  is  characterized  by  increased  ATP. 
During single-cell patch clamp recordings, when extracellu-
lar glucose is reduced but not eliminated, and the level of 
intracellular ATP is sufficient or high in the patch pipette, 
CA3  pyramidal  neurons  regulate  their  own  excitability  by 
releasing ATP, activating adenosine A1 receptors and open-
ing postsynaptic K
+ channels [96]. In contrast, during single 
cell recordings of CA3 pyramidal neurons, when extracellu-
lar  glucose  is  reduced  and  intracellular  ATP  is  low,  CA3 
pyramidal  cells  depolarize  significantly  [96].  These  low 
ATP/low glucose conditions are similar to an ischemic stroke, 
where both oxidative phosphorylation and glucose availabil-
ity  are  interrupted.  Thus,  an  autocrine  regulation  of  CA3 
neuron excitability during low glucose depends critically on 
intracellular  ATP;  the  subsequently  increased  extracellular 
adenosine likely influences nearby neurons, particularly im-
portant in CA3, a region with recurring excitatory collaterals. 
Overall this concurrent intracellular ATP / extracellular glu-
cose manipulation mimicking metabolic aspects of ketogenic 
diet therapy provides a clear example of a situation where 
intracellular  ATP  is  high  yet  extracellular  adenosine  in-
creases – ideal for autocrine regulation by increasing seizure 
threshold and promoting neuronal survival.  
  Evidence for autocrine neuronal regulation is consistent 
with adenosine’s role as a neuroprotective agent, mobilized 
proactively  under  these  conditions  by  non-pathological 
changes in altered metabolism. Similarly, ketone-based me-
tabolism  [35]  or  a  ketogenic  diet  [70]  has  already  shown 
neuroprotective properties in injury models in multiple brain 
regions.  While  it  seems  counterintuitive  for  brain  cells  to 
release  ATP  when  extracellular  glucose  is  low,  ultimately 
this process can save cell energy: under conditions of suffi-
cient ATP, there is a large ratio of ATP:adenosine (10,000:1) 
inside the cell. Upon releasing a relatively small amount of 
ATP,  a  coherent  set  of  mechanisms  degrade  extracellular 
ATP to adenosine, activate adenosine A1 receptors and re-
duce excitability. Thus, releasing a relatively small amount 
of ATP during low glucose is a powerful preemptive strike 
against  a  condition  of  increased  excitability  –  potentially 
placing energy demands which could exceed energy supply 
and compromise neuronal function.  
CLINICAL IMPLICATIONS 
  The  clinical  efficacy  of  a  ketogenic  diet  is  well-estab-
lished for pediatric epilepsy. It has been validated retrospec-
tively by multiple clinical sites [38, 62, 153, 188] and con-
firmed recently in a randomized controlled trial [135]. Simi-
lar to adenosine, the ketogenic diet is effective in medically-
refractory  epilepsy,  and  thus  reduces  seizures  via  mecha-
nisms other than those targeted by antiepileptic drugs avail-
able  currently  [168].  A  significant  subset  of  pediatric  epi-
lepsy patients become and remain seizure-free, and can re-
duce or eliminate their medication even after discontinuing 
diet therapy. Most common side effects are short term, and 
include hunger, constipation, and lethargy [135, 188]. How-
 
 
 
 
 
 
 
 
 
 
Fig. (1). The metabolic relationship between ketones and adenosine. Compounds upregulated by a ketogenic diet or exogenous ketones are 
italicized. (1) During ketolytic metabolism, the ketone bodies β-hydroxybutyrate (and its breakdown products acetone and acetoacetate) are 
either generated locally or hepatically and transported via the blood to other tissues (such as brain). Ketones are converted intracellularly into 
acetyl-CoA which enters the tricarboxylic acid cycle. (2) This mitochondrial energy cycle generates, at multiple steps (----), protons and elec-
trons that are channeled to the electron transport chain by NADH and FADH2 (β-hydroxybutyrate conversion to acetoacetate also contrib-
utes). Many steps of the tricarboxylic acid cycle are omitted for simplicity. (3) The electron transport chain drives an electrochemical gradi-
ent across the mitochondrial outer membrane and ultimately oxidative phosphorylation which forms ATP from ADP and phosphate (Pi) by 
ATP synthase. (4) Enhanced ATP can be converted to phosphocreatine for energy storage, or broken down to its core molecule, adenosine. 
Adenosine levels inside and outside of the cell membrane are influenced concurrently by an equilibrative transporter. Due to the very large 
ATP / adenosine ratio inside the cell, a small increase in intracellular ATP could translate into a large relative increase in intracellular, and 
thus extracellular, adenosine. Adenosine, Ketogenic Diet and Epilepsy  Current Neuropharmacology, 2009, Vol. 7, No. 3    261 
ever, kidney stones can develop in 5-7% of children on the 
diet [171].  
  The ketogenic diet may also offer benefits for adult epi-
lepsy [15], and recently has been shown to improve dramati-
cally or even reverse the metabolic syndrome which charac-
terizes type II diabetes [198]. Notably, a ketogenic diet was 
more effective than a calorically restricted diet, and virtually 
reversed metabolic syndrome in all persons who were able to 
comply with the restrictions of dietary therapy [192]. Basic 
research has also shown dramatic results in slowing tumor 
growth in brain cancer [177], and synergistic effects of the 
simultaneous  use  of  a  ketogenic  diet  and  2-deoxyglucose 
[121],  a  metabolic  manipulation  which  inhibits  glycolysis, 
increases adenosine [200] and decrease seizures [69, 181]. 
Thus,  the  therapeutic  applications  of  a  ketogenic  diet  and 
metabolism-based  therapies  are broadening rapidly beyond 
pediatric epilepsy to other chronic and prevalent conditions.  
  As a whole, the capacity for a ketogenic diet to increase 
specifically  the  influence  of  endogenous  adenosine  offers 
testable  and  clinically-relevant  predictions;  many  of  these 
predictions are validated by published clinical and basic re-
search, lending further conceptual support [125, 126]. Below 
we highlight briefly some of the central nervous system im-
plications  of  a  relationship  between  a  ketogenic  diet  and 
adenosine. A subset is supported strongly by published re-
search,  in  particular  neuroprotection  and  sleep.  Data  are 
emerging  for  neurodegeneration,  hyperdopaminergic  disor-
ders and autism. In addition, we speculate upon major clini-
cal implications for pain.  
Brain Injury 
  The  attractive  features  of  adenosine  as  an  endogenous 
anticonvulsant are recapitulated in its role as a neuroprotec-
tive  molecule.  Increasing  adenosine’s  inhibitory  influence 
via the adenosine A1 receptor protects neurons in virtually 
any model of brain injury [45], and the adenosine A1 recep-
tor has long been a major focus of and goal for adenosine-
based neuroprotective therapies. Increasing the influence of 
adenosine at A1 receptors offers neuroprotection either be-
fore [90] or after [190] the injury. Unfortunately, and akin to 
epilepsy, the peripheral side effects of receptor-based strate-
gies have stymied drug development and adenosine A1 re-
ceptors have lost  momentum  as  a primary neuroprotective 
target.  
  Importantly,  and  as  predicted  based  on  a  relationship 
between  ketone  metabolism  and  adenosine,  the  ketogenic 
diet or analogous metabolic strategies have shown neuropro-
tective properties in multiple brain injury models and brain 
regions,  including spinal  cord injury [160]. Some of these 
effects  have  been  counterintuitive  –  neuroprotection  was 
observed after a ketogenic strategy such as fasting [35], or 
after strategies that interrupted metabolism [102] or inhibited 
glycolysis [111]. Importantly, neuroprotection was observed 
even  if  altered  metabolism  was  initiated  after  the  injury 
[152], making this a particularly promising strategy. Based 
on  differential  consequences  and  responses  in  the  central 
nervous system versus the periphery (Table 2), a metabolic 
strategy could lend new therapies and recommendations for 
the treatment of brain injuries, and open a new and exciting 
chapter for adenosine and neuroprotection. 
Neurodegeneration  
  The neuroprotective effects of adenosine via altered me-
tabolism  may  extend  to  neurodegenerative  diseases.  Meta-
bolic dysregulation at the cellular level is a hallmark of many 
chronic and neurodegenerative disorders [7], and often it is 
unclear if it causes and/or results from the progressive neu-
ronal dysfunction. The brain has an extremely high fat con-
tent,  and  as  noted  in  Table 2   offers  some  differential  re-
sponses to metabolic manipulations as compared to periph-
eral tissues. These dual and unique features of brain compo-
sition and brain metabolism enhance therapeutic opportuni-
ties for chronic  and progressive disorders [1], and suggest 
the potential for limited or reduced peripheral side effects.  
  As one  example, metabolic therapy may offer  sympto-
matic delay or improvement even in a genetic, neurodegen-
erative disorder such as Huntington’s disease [41, 186]. Drug 
treatments targeting type II diabetes, which, similar to a ke-
Table 2.  Influence of Ketone Metabolism on Cellular Energy 
  Energetic Molecules 
Expression of Mitochondrial  
Genes or Proteins 
Mitochondria  Respiration 
Brain 
Increased ATP [37, 99, 127, 
134, 143] 
Increased phosphocreatine [20, 
151] 
Upregulated ATP synthase [20, 141] 
Upregulated uncoupling protein 
[182] 
Unchanged succinate dehydrogenase 
[167] 
Increased number [20, 143] 
Increased or reduced number 
(region-dependent) [6] 
Increased respiration [182] 
Peripheral tis-
sues 
Unchanged ATP production 
[158] 
Unchanged citrate synthase [158] 
Unchanged succinate dehydrogenase 
[137, 167] 
Moderately increased size [48] 
Unchanged [6] 
 
Evidence for changes in cellular energy in brain and peripheral tissues after ketogenic metabolism in vivo or in vitro. An increase or upregulation is indicated by italics throughout. 
“Expression of genes or proteins” includes mRNA expression and protein expression via immunochemical or activity-based assays; here we include both cell and mitochondria-
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togenic  diet,  offer  improved  glycemic  control,  can  reduce 
symptoms  and  increase  survival  in  mouse  models  of 
Huntington’s disease [116, 122]. With gene therapy still be-
yond  the  near-term  horizon,  metabolic  treatment  strategies 
which delay or reduce symptoms of disease could offer sig-
nificant improvements in quality of life for current patients 
with Huntington’s disease and a host of neurodegenerative 
conditions. In addition, at least some neurodegenerative dis-
eases are associated with an increased risk of seizures, such 
as Alzheimer’s disease [3]. It is unknown whether subclini-
cal seizures may occur and contribute to the progression of 
Alzheimer’s  disease  or  other  neurodegenerative  diseases  
in humans. Ultimately, similar to epilepsy, adenosine-based 
metabolic therapies could limit acute dysfunction and offer 
ongoing  neuroprotection  against  progressive  neuronal  de-
cline and degeneration. 
Sleep 
  Adenosine promotes sleep [165, 189], and treating sleep 
disorders and enhancing the quality of sleep is a major con-
cern  for  public  health  [23].  The  specific  adenosine-based 
mechanism established initially as sleep-promoting was in-
creased  activity  at  the  A1  receptor  in  the  basal  forebrain 
[166]. More recently  the adenosine A2A receptor has been 
recognized  for  an  important  role  in  sleep  [88,  174].  The 
alerting  effects  of  caffeine  are  attributed  to  its  actions  at 
adenosine receptors in forebrain areas important for cogni-
tion as well as arousal centers, and it may be that endoge-
nous  adenosine  acting  at  both  of  the  receptor  subtypes  in 
brain that are antagonized by caffeine – A1 and A2A adeno-
sine receptors – play a role in sleep behaviors [8].  
  In keeping with adenosine’s role as a sleep-promoter, and 
the potential for a ketogenic diet to increase ATP and ex-
tracellular adenosine, the ketogenic diet has been shown to 
improve sleep quality and quantity in children with epilepsy, 
especially normalizing the ultradian cycling between slow-
wave  and  paradoxical  sleep  [83].  Sleep  electroencephalo-
graph (EEG) changes were observed consistently with keto-
genic  diet  therapy,  and  normalization  or  improvement  in 
sleep EEG was correlated with an improvement in seizures 
[153].  In  control  subjects  without  a  diagnosis  of  epilepsy, 
effects are typically moderate and include reports of an in-
crease  in the latency  to enter rapid eye movement (REM) 
sleep [106] and an increase in slow-wave sleep [2]. Whereas 
a high-fat, low-carbohydrate ketogenic diet increased slow-
wave sleep, a high-carbohydrate, low-fat isocaloric diet de-
creased slow-wave sleep [159].  
  Recent evidence implicates the role of extracellular as-
trocyte-derived ATP as critical for the sleep-promoting in-
fluence of adenosine [82]. Furthermore, there is a well estab-
lished  association  between  poor  sleep  and  epilepsy  [105]. 
With such a high prevalence and cost associated with these 
co-morbidities, metabolic therapy appears to offer significant 
promise. More research is needed in this area to determine 
the  therapeutic  relationship  among  adenosine,  a  ketogenic 
diet and sleep.  
Autism 
  Multiple lines of evidence suggest that the influence of 
adenosine may be insufficient in autism spectrum disorders 
(ASD),  and  that  increasing  adenosine  would  reduce  both 
physiological and behavioral hallmarks of ASD. Preliminary 
studies have shown that the ketogenic diet improves symp-
toms of autism [53], and Rett syndrome [80]. To our knowl-
edge, dysregulation of adenosine in brain has not been tested 
directly with respect to symptoms of autism, although these 
studies  are  underway.  Nevertheless,  adenosine  is  a  purine 
molecule with roles in both metabolism and neuronal signal-
ing,  and  abnormalities  in  purine  metabolism  have  been 
documented [19, 120, 142, 149, 150] in a subset of ASD. 
  Along with dysregulation of purine metabolism, ASD are 
characterized by several behavioral and physiological hall-
marks  of  disordered  adenosine:  sleep  disruption  [25,  72, 
184], markedly increased incidence of seizures [118, 195], 
immune dysfunction [87, 91], and reports - including self-
reports - of increased anxiety and “sensitivity” and “hyperac-
tivity” of the nervous system [24, 78, 178]. Often there is a 
dual  diagnosis,  with  psychiatric  comorbidities  present  in 
least  70%  of  individuals  diagnosed  with  ASD.  The  most 
common comorbidities are social anxiety disorder, attention-
deficit/hyperactivity disorder, and oppositional defiant disor-
der [178].  
  Many of the behaviors exhibited by persons with autism 
and/or  reported  by  high-functioning  persons  with  autism 
involve  stimuli  that  would  be  predicted  to  release  ATP 
and/or adenosine based on associated mechanical pressure, 
increased neuronal activity, decreased pH or increased tem-
perature (ref. [45] and Table 1). For example, rocking, spin-
ning and Grandin’s well-known “Hug Machine” [49] all ex-
ert mechanical pressure or sudden changes in acceleration, 
intense  intellectual  activity  and  focus  can  reduce  anxiety 
associated with ASD [78], and intense neuronal activity in-
creases extracellular adenosine [114]. Intense exercise causes 
a  metabolic  decrease  in  pH  [84],  decreased  pH  has  been 
shown to increase adenosine [42, 146], and intense exercise 
has  been  shown  to  increase  brain  adenosine  [47]  and  im-
prove  symptoms  of  autism  [98].  Reports  show  improved 
behavior,  language  and  social  function  associated  with  a 
fever in persons with autism [30], and basic research demon-
strates  that  a  similar  temperature  increase  in  hippocampal 
slices increases extracellular adenosine and inhibits neuronal 
activity significantly [124]. 
  Certainly many symptoms and behaviors of ASD are due 
to  aberrant  neurochemistry,  neuroanatomical  development 
and genetically-determined substrates. However, increasing 
the inhibitory influence of adenosine could help significantly 
with multiple behavioral and physiological sequelae. Impor-
tantly, increasing  adenosine  improves sleep, decreases sei-
zures  and  reduces  anxiety  –  all  physiological  effects  that 
could be achieved by a metabolic strategy such as a keto-
genic diet and would improve quality of life significantly in 
persons and families affected by ASD. Ketogenic diet ther-
apy  and/or  increasing  adenosine  could  improve  social  and 
behavioral symptoms and reduce or alleviate serious chronic 
physiological  symptoms  which  impact  the  ability  to  learn 
and  remember  (sleep  disruption/inadequate  REM  sleep/ 
seizures  [86,  118])  and  ultimately  cause  permanent  brain 
dysfunction  and  cognitive  impairment  (recurrent  seizures) 
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activity, sleep and seizures, the relationship among metabo-
lism, autism and adenosine, including the efficacy of a keto-
genic diet in reducing symptoms of autism, needs to be ex-
plored directly. 
Hyperdopaminergic Disorders 
  Dopamine  and  adenosine  have  long  been  known  to be 
opposing at numerous levels. Behaviorally, whereas adeno-
sine receptor antagonists (e.g. caffeine) are stimulants, such 
properties belong to agonists of the dopamine system (e.g. 
amphetamine). Biochemically, the two high affinity adeno-
sine receptors in brain each have an antagonistic dopaminer-
gic counterpart. Specifically, A1 and D1 receptors, and A2A 
and  D2  receptors,  have  opposing  effects  on  2
nd  messenger 
pathways,  most  notably  the  production  of  cyclic  AMP 
through  heterotrimeric  G-protein  regulation  of  adenylate 
cyclase [61, 97]. More recently, it has become apparent that 
such interactions can involve direct receptor/receptor cross-
talk via A1/D1 and A2A/D2 receptor heteromers [54]. There-
fore, it is logical to explore modulation of adenosinergic ac-
tivity as a possible treatment for disorders of dopaminergic 
function.  
  Thus far there is compelling evidence that adenosine an-
tagonists are useful in treating a hypodopaminergic disease, 
namely Parkinson’s disease [197]. Conversely, the ketogenic 
diet and an associated augmentation of adenosine may be of 
use in hyperdopaminergic states. The list of clinical condi-
tions that are hypothesized to involve overactivity in the do-
pamine system is impressive, and includes conditions as di-
verse  as  schizophrenia,  tardive  dyskinesia,  attention  defi-
cit/hyperactivity disorder, Tourette’s syndrome, Huntington’s 
disease,  and  drug  addiction/relapse.  Research  in  animal 
models  of  some  of  these  disorders  suggests  the  beneficial 
effects of promoting adenosine [12, 14, 39, 71, 92, 101, 113, 
191]. Adenosine augmentation via ketogenic diet or analo-
gous metabolic strategies may be particularly useful in those 
hyperdopaminergic  disorders  involving  neurodegeneration, 
offering the combined benefits of treating symptoms as well 
as retarding the underlying degeneration.  
  Preliminary human data exist on the benefits of ketogenic 
diet therapy and schizophrenia [148]. Ketogenic diet therapy 
was  tried  because  the  physiological  effects  of  other  treat-
ments  –  such  as  electroconvulsive  shock  –  result  in  de-
creased  blood  pH,  and  ketone  metabolism  increases  acid 
production. In addition, physicians noted carbohydrate crav-
ings and increased intake prior to a relapse and hypothesized 
that  persons  with  schizophrenia  may  have  problematic  or 
altered carbohydrate metabolism. Despite the small sample 
size and incomplete control over dietary therapy, promising 
results were noted [148].  
  Like epilepsy, schizophrenia is a chronic condition char-
acterized by recurring episodes as well as significant propor-
tion  of  cases  that  remain  intractable  to  therapies  available 
currently [107]. Finally, given the high coincident rates of 
epilepsy  and schizophrenia [164] and type II diabetes and 
schizophrenia [39, 139, 144, 179], and the success of a vari-
ety of low carbohydrate and ketogenic diets in treating type 
II  diabetes  [198]  and  adult  epilepsy  [5,  103,  104],  dietary 
therapy  would  seem  like  an  optimal  primary  or  adjuvant 
therapy to reduce all of these medical conditions. 
Pain  
  Control of chronic pain remains a major clinical problem. 
For example, the strongest analgesics, the opiates, have been 
viewed  historically  as  poorly  effective  against  neuropathic 
pain; only a subset of patients respond well to opiates [163]. 
Anticonvulsant drugs are a non non-opiate alternative used 
with  success  against  neuropathic  pain,  yet  they  have  their 
own set of undesirable side effects. Pain relief using anticon-
vulsants demonstrates that an overall inhibition of neuronal 
activity is a strategy that can alleviate pain, and so it is not 
surprising that adenosine persists as a prized, but problem-
atic, target for pain relief [180]. Adenosine A1 receptor ago-
nists given systemically reduce chronic pain  effectively in 
experimental  animals  [31,  112],  and  conversely,  genetic 
knockout of the A1 receptor enhances pain sensitivity [90, 
196].  Clinically,  systemic  adenosine  alleviates  neuropathic 
pain [10], yet the presence of adenosine A1 receptors in the 
heart  and other peripheral tissues,  and the short biological 
half-life of adenosine in the blood, have stymied this type of 
therapy. Side effects can be avoided with intrathecal adeno-
sine [9, 50], but this route of administration is obviously in-
vasive.  
  Based  on  evidence  that  ketogenic  strategies  increase 
adenosine in the  central nervous system, they will also be 
likely to alleviate pain, although research on this topic has 
only begun [203]. The parallels between ketogenic diets and 
adenosine  A1  receptor  activation  include  their  efficacy  in 
pharmocoresistant epilepsy, and neuronal inhibition via anti-
convulsants appears to be one mechanism for alleviating at 
least a subset of neuropathic pain. We suggest that adeno-
sine-mediated  central  nervous  system  inhibition  via  meta-
bolic strategies such as ketogenic diet therapy will be effec-
tive against neuropathic pain.  
  Beyond these possible effects on the neural substrates of 
pain generally, a ketogenic metabolism may have beneficial 
effects  with  inflammatory  pain  by  reducing  inflammation 
itself through several mechanisms. 1) adenosine A1 receptors 
have  been  shown  to  be  anti-inflammatory  in  a  number  of 
tissues, including brain [68, 110, 183, 185]. 2) Compared to 
glycolytic metabolism, ketolytic metabolism produces fewer 
reactive oxygen species, which are known to contribute to 
inflammation [81, 117, 187]; 3) the long-chain polyunsatu-
rated fatty  acids  in  the ketogenic diet activate peroxisome 
proliferator-activated receptors, an effect which will reduce 
inflammation by inhibiting nuclear factor κB and other pro-
inflammatory pathways [13, 32, 33, 115]. Altogether, multi-
ple consequences of ketone metabolism, including increased 
adenosine,  appear  to  have  much  clinical  promise  as  safe, 
effective,  non-addictive  treatments  for  chronic  neuropathic 
and inflammatory pain conditions.  
SUMMARY 
  Herein we highlight major implications of the emerging 
relationship among adenosine, a ketogenic diet and epilepsy 
and provide a broad and provocative overview of a subset of 
the  therapeutic  predictions  of  this  metabolic  relationship. 
The clinical implications discussed in detail are supported by 
preliminary or historical data, or by infrequent publication in 
disparate fields of research, and deserve further examination 
and integration. An evidence–based metabolic treatment as 264    Current Neuropharmacology, 2009, Vol. 7, No. 3  Masino et al. 
an adjuvant or alternate strategy is particularly attractive and 
important as we seek cost-effective solutions for the diverse 
conditions  highlighted  herein.  Together  these  conditions 
exact an enormous toll on health care and quality of life as 
they are chronic, prevalent, increasing (particularly diabetes 
and autism), and often  comorbid (sleep disorders and  epi-
lepsy, for example).  
  In the central nervous system, adenosine offers unparal-
leled yet untapped opportunities for seizure protection, neu-
roprotection,  sleep,  and  pain  relief,  among  others.  Under-
standing  the  regulation  of  adenosine  helps  achieve  these 
long-standing clinical goals and extends beyond them to al-
leviating  both  acute  and  chronic  conditions  in  adults  and 
children.  In  summary,  the  metabolic  relationship  among 
adenosine, a ketogenic diet, and epilepsy could open major 
new  therapeutic  applications  and  avoid  peripheral  side  ef-
fects in a way that has eluded receptor-based strategies.  
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